Sebastian Rogenhofer
Overview
Explore the profile of Sebastian Rogenhofer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller S, Rogenhofer S
Aktuelle Urol
. 2020 Nov;
51(6):593-610.
PMID: 33233002
No abstract available.
2.
Ellinger J, Schneider A, Bachmann A, Kristiansen G, Muller S, Rogenhofer S
Anticancer Res
. 2016 Jul;
36(8):3961-4.
PMID: 27466500
Background/aim: Alterations of global histone modification levels have been identified in various tumor entities, including bladder cancer (BCA). Our study was designed to investigate the value of global histone acetylation...
3.
Ahmadzadehfar H, Schlenkhoff C, Rogenhofer S, Yordanova A, Essler M
Clin Nucl Med
. 2016 Jul;
41(9):695-6.
PMID: 27405025
A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra. Before the first therapy and 4 weeks...
4.
Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff C, et al.
Oncotarget
. 2016 Feb;
7(11):12477-88.
PMID: 26871285
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand...
5.
Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al.
EJNMMI Res
. 2015 Jun;
5(1):114.
PMID: 26099227
Background: Radioligand therapy (RLT) with (177)Lu-DKFZ-617 PSMA (Lu-PSMA) (prostate-specific membrane antigen) is a novel targeted therapy of metastatic prostate cancer. We analysed retrospectively the early side effects and the response...
6.
Isaak A, Hauser S, Rogenhofer S, Schmidt-Wolf I
Anticancer Res
. 2015 Mar;
35(3):1575-82.
PMID: 25750313
Background/aim: Although targeted-therapy (TT) for patients with metastatic renal cell cancer (mRCC) has shown an improved outcome, their prognosis is still very poor. Immunotherapy with dendritic cells (DC) as one...
7.
Ellinger J, Bachmann A, Goke F, Behbahani T, Baumann C, Heukamp L, et al.
Urol Int
. 2014 Feb;
93(1):113-8.
PMID: 24556868
Background: Epigenetic alterations, including histone modifications, play an important role during carcinogenesis. This study was designed to systematically investigate histone H3K9 and H3K27 methylation levels in bladder cancer (BCa) tissue....
8.
Latz S, Achterberg M, Ellinger J, Engels T, Hauser S, Rogenhofer S, et al.
Urol Int
. 2013 Sep;
92(2):237-41.
PMID: 24051578
Introduction: To evaluate the meaning of urodynamic parameters in patients with pouch incontinence. Materials And Methods: Thirteen urodynamic studies in patients with an ileal nipple as the efferent segment of...
9.
Jakel C, Hauser S, Rogenhofer S, Muller S, Brossart P, Schmidt-Wolf I
Clin Dev Immunol
. 2012 Nov;
2012:473245.
PMID: 23193418
Metastatic renal cell carcinoma (RCC) seems to be resistant to conventional chemo- and radiotherapy and the general treatment regimen of cytokine therapy produces only modest responses while inducing severe side...
10.
Rogenhofer S, Hauser S, Breuer A, Fechner G, Mueller S, Oldenburg J, et al.
World J Urol
. 2012 Nov;
31(3):703-7.
PMID: 23179730
Purpose: To determine retrospectively the perioperative management and outcome of transurethral prostate/bladder surgery (TURP, TURB) and transrectal prostate biopsy in hemophiliacs. Methods: Thirty-seven hemophilic patients underwent TURP (12 patients), TURB...